SCHEMBL6955775

SCHEMBL6955775

N[CH]CCCCCCCCCCCN

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 0.53
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA3 P07451 2/20 0.53
CA4 P22748 2/20 0.53
CA6 P23280 2/20 0.53
CA5A P35218 2/20 0.53
CA7 P43166 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53
CA5B Q9Y2D0 2/20 0.53
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
BLM P54132 1/20 0.53
NFKB1 P19838 1/20 0.47
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 1/20 0.40
EPHX1 P07099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28262020 1.00 DNM1 (0.53) DNM1CA12CA1CA2CA3
SCHEMBL6609179 1.00
SCHEMBL654031 1.00
SCHEMBL29084246 1.00 DNM1 (0.53) DNM1CA12CA1CA2CA3
SCHEMBL652435 0.97
SCHEMBL353057 0.86
SCHEMBL5300768 0.86
SCHEMBL5304496 0.86
SCHEMBL5304490 0.86
SCHEMBL4400603 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102676624-A Method for producing active peptide from peanut cake and meal by immobilized enzyme HENAN ACADEMY AGRICULTURAL SCI 2012-09-19 CN claimed
CN-102471466-A Copolymer made of a polyphenylene and a flexible chain component BOSCH GMBH ROBERT 2012-05-23 CN claimed
CN-102365308-A Polyisobutylene-based polyurethanes POLYISOBUTYLENE BASED POLYURETHANES 2012-02-29 CN claimed
CN-102838947-A Modifier for adhesive, method for producing same, adhesive, and circuit connection structure HITACHI CHEMICAL CO LTD 2012-12-26 CN disclosed
CN-102834373-A Method for producing carbamate compound, and method for producing isocyanate compound using same ASAHI GLASS CO LTD 2012-12-19 CN disclosed
CN-102816346-A Dialkylphosphinic acid fire retardant containing primary amine groups and preparation method thereof UNIV JIANGHAN 2012-12-12 CN disclosed
CN-101925625-B Medical adhesive for surgical operation BAYER MATERIALSCIENCE AG 2012-12-05 CN disclosed
CN-102803387-A Semi-aromatic, semi-crystalline copolyamides BASF SE 2012-11-28 CN disclosed
CN-102781987-A Thermosetting resin having benzoxazine ring and method for producing same SEKISUI CHEMICAL CO LTD 2012-11-14 CN disclosed
CN-102782010-A Process for production of polypentamethyleneadipamide resin TORAY INDUSTRIES 2012-11-14 CN disclosed
CN-102731877-A Injection molded body having excellent barrier property MITSUBISHI GAS CHEMICAL CO 2012-10-17 CN disclosed
CN-101175821-B Flame retardant polyamide composition MITSUI CHEMICALS, INC. (JP) 2012-02-15 CN disclosed
CN-1954014-B Polyamide resin and hinged molded article MITSUBISHI CHEMICAL CORP. (JP) 2012-02-08 CN disclosed
CN-102336959-A Injection molded body having excellent barrier property MITSUBISHI GAS CHEMICAL CO 2012-02-01 CN disclosed
CN-101443382-B Polyamide resin MITSUBISHI CHEMICAL CORP. (JP) 2012-02-01 CN disclosed
CN-101652429-B Flame-retardant polyamide composition MITSUI CHEMICALS INC 2012-01-25 CN disclosed
US-6646129-B2 Treatment of psoriasis and skin cancer LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-11-11 US disclosed
EP-0984936-B1 CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS LEO PHARMA AS WITH SECONDARY N (DK) 2003-09-03 EP disclosed
US-20020107400-A1 Cyanoguanidines as cell proliferation inhibitors LEO PHARMACEUTICAL PRODUCTS LTD. A/S 2002-08-08 US disclosed
US-6346520-B1 ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 2002-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107400-A1 Cyanoguanidines as cell proliferation inhibitors CCNC, MKI67, CCNI DNM1 1386/4885CA12 1483/4885CA1 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.